Literature DB >> 31721034

Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area.

Daisuke Nakamura1,2, Makoto Yoshimitsu3, Tomohisa Tabuchi4,3, Naosuke Arima4,3, Maiko Hayashida4,3, Hirosaka Inoue4,3, Kakushi Matsushita4,3, Tadashi Matsumoto4, Naomichi Arima3, Kenji Ishitsuka3.   

Abstract

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell neoplasm associated with the human T-cell leukemia virus type-I (HTLV-1); prognosis still remains very poor. We retrospectively reviewed the treatment of 198 patients with acute-, lymphoma- and unfavorable chronic-type ATL (aggressive ATL) diagnosed from 2005 to 2014 in a hospital located in an area of Japan in which HTLV-1 is highly endemic. One-hundred forty-three, and 35 patients were treated using OPEC/MPEC and VCAP-AMP-VECP, respectively. OPEC/MPEC was mainly used until around 2010, and gradually switched to VCAP-AMP-VECP, especially for younger patients. The 2-year overall survival for patients treated by VCAP-AMP-VECP was significantly higher than that using OPEC/MPEC for patients < 70 years old (y.o.), but not for patients ≥ 70 y.o. A less intensive chemotherapy OPEC/MPEC could be performed without reducing dose intensity, even in elderly patients, and its therapeutic outcome is not inferior to that of VCAP-AMP-VECP. It is difficult to draw definite conclusion from this small retrospective study; however, OPEC/MPEC may represent an alternative option for elderly patients with aggressive ATL.

Entities:  

Keywords:  ATL; HTLV-1; OPEC/MPEC; RDI; VCAP-AMP-VECP

Mesh：

Year:  2019        PMID： 31721034     DOI： 10.1007/s12185-019-02769-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  17 in total

1.  Adult T-cell leukemia: clinical and hematologic features of 16 cases.

Authors:  T Uchiyama; J Yodoi; K Sagawa; K Takatsuki; H Uchino
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

Review 2.  Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.

Authors:  Hiroaki Miyoshi; Koichi Ohshima
Journal:  Int J Hematol       Date:  2018-03-03       Impact factor: 2.490

3.  Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.

Authors:  Takashi Ishida; Hiroshi Fujiwara; Kisato Nosaka; Naoya Taira; Yasunobu Abe; Yoshitaka Imaizumi; Yukiyoshi Moriuchi; Tatsuro Jo; Kenichi Ishizawa; Kensei Tobinai; Kunihiro Tsukasaki; Shigeki Ito; Makoto Yoshimitsu; Maki Otsuka; Michinori Ogura; Shuichi Midorikawa; Wanda Ruiz; Tomoko Ohtsu
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

4.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

5.  Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

Authors:  M Shimoyama
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

6.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

Authors:  Kunihiro Tsukasaki; Atae Utsunomiya; Haruhiko Fukuda; Taro Shibata; Takuya Fukushima; Yoshifusa Takatsuka; Shuichi Ikeda; Masato Masuda; Haruhisa Nagoshi; Ryuzo Ueda; Kazuo Tamura; Masayuki Sano; Saburo Momita; Kazunari Yamaguchi; Fumio Kawano; Shuichi Hanada; Kensei Tobinai; Masanori Shimoyama; Tomomitsu Hotta; Masao Tomonaga
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

7.  Treatment and survival among 1594 patients with ATL.

Authors:  Hiroo Katsuya; Kenji Ishitsuka; Atae Utsunomiya; Shuichi Hanada; Tetsuya Eto; Yukiyoshi Moriuchi; Yoshio Saburi; Masaharu Miyahara; Eisaburo Sueoka; Naokuni Uike; Shinichiro Yoshida; Kiyoshi Yamashita; Kunihiro Tsukasaki; Hitoshi Suzushima; Yuju Ohno; Hitoshi Matsuoka; Tatsuro Jo; Masahiro Amano; Ryosuke Hino; Mototsugu Shimokawa; Kazuhiro Kawai; Junji Suzumiya; Kazuo Tamura
Journal:  Blood       Date:  2015-09-11       Impact factor: 22.113

Review 8.  Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.

Authors:  Kenji Ishitsuka; Kazuo Tamura
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

9.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.

Authors:  Kunihiro Tsukasaki; Olivier Hermine; Ali Bazarbachi; Lee Ratner; Juan Carlos Ramos; William Harrington; Deirdre O'Mahony; John E Janik; Achiléa L Bittencourt; Graham P Taylor; Kazunari Yamaguchi; Atae Utsunomiya; Kensei Tobinai; Toshiki Watanabe
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.

Authors:  Takashi Ishida; Tatsuro Jo; Shigeki Takemoto; Hitoshi Suzushima; Kimiharu Uozumi; Kazuhito Yamamoto; Naokuni Uike; Yoshio Saburi; Kisato Nosaka; Atae Utsunomiya; Kensei Tobinai; Hiroshi Fujiwara; Kenji Ishitsuka; Shinichiro Yoshida; Naoya Taira; Yukiyoshi Moriuchi; Kazunori Imada; Toshihiro Miyamoto; Shiro Akinaga; Masao Tomonaga; Ryuzo Ueda
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.